# NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

> **NCT04930783** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** CDX-301
- **BIOLOGICAL:** NEOVAX
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04930783
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-09-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930783, "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04930783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*